Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ B-ALL). We're looking at two groups of adults: one group had an Allogeneic Stem Cell Transplant (alloHCT) cohort A, and the other group had chimeric antigen receptor T cell (CAR T) therapy, cohort B. We also want to figure out what the best dose of asciminib is to use moving forward in future studies.

NCT Number	NCT07250087
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: Novartis
Conditions	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Enrollment	36 participants
Start Date	2026-01-21
Primary Completion	2029-11 (estimated)
Study Completion	2029-11 (estimated)
Updated on ClinicalTrials.gov	2026-03-27